小主动脉瓣环重度主动脉瓣狭窄的TAVR与SAVR随机对照试验
这项国际多中心随机试验纳入151例小主动脉瓣环(平均直径<23 mm)的重度主动脉瓣狭窄患者,1:1随机接受TAVR或SAVR。60天时两组瓣膜血流动力学不良结局(严重患者-人工瓣膜不匹配或中重度主动脉瓣反流)无差异,中位随访2年临床事件也无差异;但样本量有限导致研究把握度不足,结论需更大规模研究确认。
要点
- 小主动脉瓣环重度主动脉瓣狭窄患者中,TAVR与SAVR在60天瓣膜血流动力学方面无 superiority 证据。
- 中位随访2年,两组死亡率、卒中和心脏住院率均无显著差异。
- 治疗选择应个体化,结合基线特征、解剖风险因素和患者偏好。
核心结论
- 在重度主动脉瓣狭窄合并小主动脉瓣环(女性占多数)患者中, contemporary TAVR 相比 SAVR 在瓣膜血流动力学结果上无 superiority 证据。
- 中位随访2年,两组临床结局无差异,提示两种治疗均为有效选择,治疗决策应个体化。
研究设计与样本
- 前瞻性国际多中心随机试验,在15所大学医院开展。
- 纳入151例重度主动脉瓣狭窄且小主动脉瓣环(平均直径<23 mm)患者,1:1随机接受TAVR(n=77)或SAVR(n=74)。
- 主要终点为60天时经多普勒超声心动图评估的瓣膜血流动力学不良(严重患者-人工瓣膜不匹配或中重度主动脉瓣反流),由中心超声核心实验室分析。
主要发现
- 严重患者-人工瓣膜不匹配发生率:TAVR组4例(5.6%),SAVR组7例(10.3%),P=0.30。
- 中重度主动脉瓣反流:两组均无。
- 30天死亡率:TAVR组1例(1.3%),SAVR组1例(1.4%),P=1.00;30天卒中:TAVR组0例,SAVR组2例(2.7%),P=0.24。
- 中位随访2年(IQR 1-4年)死亡率:TAVR组7例(9.1%),SAVR组6例(8.1%),P=0.89;卒中:TAVR组3例(3.9%),SAVR组3例(4.1%),P=0.95;心脏住院:TAVR组15例(19.5%),SAVR组15例(20.3%),P=0.80。
临床怎么用
- 对于重度主动脉瓣狭窄合并小主动脉瓣环患者,TAVR和SAVR均可作为有效治疗选择。
- 治疗选择应基于基线特征、额外解剖风险因素和患者偏好进行个体化决策。
局限性
- 样本量有限导致研究把握度不足(underpowered)。
- 结果需在未来更大规模研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal treatment in patients with severe aortic stenosis and small aortic annulus (SAA) remains to be determined. This study aimed to compare the hemodynamic and clinical outcomes between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with a SAA. METHODS: This prospective multicenter international randomized trial was performed in 15 university hospitals. Participants were 151 patients with severe aortic stenosis and SAA (mean diameter <23 mm) randomized (1:1) to TAVR (n=77) versus SAVR (n=74). The primary outcome was impaired valve hemodynamics (ie, severe prosthesis patient mismatch or moderate-severe aortic regurgitation) at 60 days as evaluated by Doppler echocardiography and analyzed in a central echocardiography core laboratory. Clinical events were secondary outcomes. RESULTS: The mean age of the participants was 75.5±5.1 years, with 140 (93%) women, a median Society of Thoracic Surgeons predicted risk of mortality of 2.50% (interquartile range, 1.67%-3.28%), and a median annulus diameter of 21.1 mm (interquartile range, 20.4-22.0 mm). There were no differences between groups in the rate of severe prosthesis patient mismatch (TAVR, 4 [5.6%]; SAVR, 7 [10.3%]; P=0.30) and moderate-severe aortic regurgitation (none in both groups). No differences were found between groups in mortality rate (TAVR, 1 [1.3%]; SAVR, 1 [1.4%]; P=1.00) and stroke (TAVR, 0; SAVR, 2 [2.7%]; P=0.24) at 30 days. After a median follow-up of 2 (interquartile range, 1-4) years, there were no differences between groups in mortality rate (TAVR, 7 [9.1%]; SAVR, 6 [8.1%]; P=0.89), stroke (TAVR, 3 [3.9%]; SAVR, 3 [4.1%]; P=0.95), and cardiac hospitalization (TAVR, 15 [19.5%]; SAVR, 15 [20.3%]; P=0.80). CONCLUSIONS: In patients with severe aortic stenosis and SAA (women in the majority), there was no evidence of superiority of contemporary TAVR versus SAVR in valve hemodynamic results. After a median follow-up of 2 years, there were no differences in clinical outcomes between groups. These findings suggest that the 2 therapies represent a valid alternative for treating patients with severe aortic stenosis and SAA, and treatment selection should likely be individualized according to baseline characteristics, additional anatomical risk factors, and patient preference. However, the results of this study should be interpreted with caution because of the limited sample size leading to an underpowered study, and need to be confirmed in future larger studies. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03383445.
引用
- Rodés-Cabau J, Ribeiro HB, Mohammadi S, et al. Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial. Circulation. 2023. PMID: 37883682. doi:10.1161/CIRCULATIONAHA.123.067326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。